The clinical application of TACE combined with RFA and sorafenib in treating recurrent hepatocellular carcinoma after surgery
10.3969/j.issn.1008-794X.2015.12.010
- VernacularTitle:TACE联合RFA及索拉菲尼在肝癌外科术后复发治疗中的临床应用
- Author:
Yuan FU
;
Jiansong JI
;
Jianfei TU
;
Jingjing SONG
- Publication Type:Journal Article
- Keywords:
chemoembolization;
radiofrequency ablation;
sorafenib;
hepatocellular carcinoma;
surgical resection
- From:
Journal of Interventional Radiology
2015;24(12):1067-1071
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical value of transcatheter arterial chemoembolization (TACE) together with radiofrequency ablation (RFA) and sorafenib in treating recurrent hepatocellular carcinoma (HCC) after surgery.Methods A total of 40 patients with recurrent HCC after surgery, who were encountered at authors' hospital during the period from December 2009 to May 2014, were collected. The patients were divided into the study group (n=20) receiving TACE combined with RFA and sorafenib and the control group (n=20) receiving TACE plus RFA. Within 7-10 days after TACE, RFA was carried out. In the study group, oral sorafenib therapy (400 mg, two times everyday) started at 4 days after TACE. Withdrawal of sorafenib would be ordered if drug resistance occurred. Each patient underwent TACE combined with RFA not less than two times. Results The median survival time of the study group and the control group was 31.0 months and 24.8 months respectively, and statistically significant difference existed between the two groups (P<0.05). The one-year, 2-year and 3-year survival rates of the study group were 85%, 70% and 50%respectively, while the one-year, 2-year and 3-year survival rates of the control group were 80%, 55% and 30% respectively; the differences between the two groups were not statistically significant (P>0.05). The progression free survival (PFS) time of the study group and the control group was 6.8 months and 5.7 months respectively, the difference between the two groups was statistically significant (P<0.05). Conclusion TACE combined with RFA and sorafenib can prolong the overall survival time and the progression free survival time of patients with recurrent HCC after surgery.
